medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2013, Número 5

<< Anterior Siguiente >>

Ann Hepatol 2013; 12 (5)


Primary care practitioners survey of non-alcoholic fatty liver disease

Said A, Gagovic V, Malecki K, Givens ML, Nieto FJ

Idioma: Ingles.
Referencias bibliográficas: 41
Paginas: 758-765
Archivo PDF: 136.28 Kb.


RESUMEN

sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40:1387-95.

  2. Bedogni G, Miglioli L, Masutti F, Castiglione A, Croce LS, Tiribelli C, Bellentani S. Incidence and natural course of fatty liver in the general population: the Dionysos study. Hepatology 2007; 46:1387-91.

  3. CDC Behavioral Risk Factor Surveillance System: Prevalence and Trend Data – Overweight and Obesity, U.S. Obesity Trends, Trends by State 2010 2010. Available from: http:// www.cdc.gov/obesity/stateprograms/fundedstates/ wisconsin.html - ref-brfss [Accessed April 30, 2013].

  4. Rafiq N, Younossi ZM. Nonalcoholic fatty liver disease: a practical approach to evaluation and management. Clin Liver Dis 2009; 13: 249-66.

  5. Site WHOW. Obesity and Overweight. Available from: http://www.who.int/dietphysicalactivity/publications/ facts/obesity/en/

  6. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-23.

  7. Dureja P, Mellinger J, Agni R, Chang F, Avey G, Lucey M, Said A. NAFLD recurrence in liver transplant recipients. Transplantation 2011; 91: 684-9.

  8. Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol 2008; 49: 608-12.

  9. Arslan U, Turkoglu S, Balcioglu S, Tavil Y, Karakan T, Cengel A. Association between nonalcoholic fatty liver disease and coronary artery disease. Coronary artery disease 2007; 18: 433-6.

  10. Hamaguchi M, Kojima T, Takeda N, Nagata C, Takeda J, Sarui H, Kawahito Y, et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterology: WJG 2007; 13: 1579-84.

  11. Lu H, Zeng L, Liang B, Shu X, Xie D. High prevalence of coronary heart disease in type 2 diabetic patients with nonalcoholic fatty liver disease. Archives of Medical Research 2009; 40: 571-5.

  12. Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, Day C, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007; 30: 1212-8.

  13. Chalasani N, Deeg MA, Crabb DW. Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2004; 99: 1497-502.

  14. Chiang CH, Huang CC, Chan WL, Chen JW, Leu HB. The severity of non-alcoholic fatty liver disease correlates with high sensitivity C-reactive protein value and is independently associated with increased cardiovascular risk in healthy population. Clin Biochem 2010; 43: 1399-404.

  15. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-9.

  16. Armstrong MJ, Houlihan DD, Bentham L, Shaw JC, Cramb R, Olliff S, Gill PS, et al. Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. J Hepatol 2012; 56: 234-40.

  17. Abenavoli L, Luigiano C, Larussa T, Milic N, De Lorenzo A, Stelitano L, Morace C, et al. Liver steatosis in celiac disease: the open door. Minerva gastroenterologica e dietologica 2013; 59: 89-95.

  18. Kallman JB, Arsalla A, Park V, Dhungel S, Bhatia P, Haddad D, Wheeler A, et al. Screening for hepatitis B, C and nonalcoholic fatty liver disease: a survey of community-based physicians. Alimentary pharmacology & therapeutics 2009; 29: 1019-24.

  19. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-9.

  20. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-31.

  21. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Alimentary pharmacology & therapeutics 2011; 34: 274-85.

  22. Williamson RM, Price JF, Glancy S, Perry E, Nee LD, Hayes PC, Frier BM, et al. Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care 2011; 34: 1139-44.

  23. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011; 140: 124-31.

  24. Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso F, Cristanini G, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Int Med 2000; 132: 112-7.

  25. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010; 53: 372-84.

  26. Farrell GC, Chitturi S, Lau GK, Sollano JD. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary. J Gastroenterol Hepatol 2007; 22: 775-7.

  27. Barlow SE. Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. Pediatrics 2007; 120(Suppl. 4): S164-S192.

  28. Loria P, Adinolfi LE, Bellentani S, Bugianesi E, Grieco A, Fargion S, Gasbarrini A, et al. Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. Dig Liver Dis 2010; 42: 272-82.

  29. Fan JG, Jia JD, Li YM, Wang BY, Lu LG, Shi JP, Chan LY. Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: update 2010: (published in Chinese on Chinese Journal of Hepatology 2010; 18:163-166). J Dig Dis 2011; 12: 38-44.

  30. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, et al. The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012; 142: 1592-609.

  31. Grattagliano I, D’Ambrosio G, Palmieri VO, Moschetta A, Palasciano G, Portincasa P. Improving nonalcoholic fatty liver disease management by general practitioners: a critical evaluation and impact of an educational training program. Journal of gastrointestinal and liver diseases: JGLD 2008; 17: 389-94.

  32. Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, Fava JL, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010; 51: 121-9.

  33. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362: 1675-85.

  34. Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann- Heurtier A, Serfaty L, Podevin P, et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 2008; 135: 100-10.

  35. Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, Austin AS, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008; 135: 1176- 184.

  36. Mathurin P, Hollebecque A, Arnalsteen L, Buob D, Leteurtre E, Caiazzo R, Pigeyre M, et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology 2009; 137: 532-40.

  37. Johnston KN, Young M, Grimmer-Somers KA, Antic R, Frith PA. Why are some evidence-based care recommendations in chronic obstructive pulmonary disease better implemented than others? Perspectives of medical practitioners. International Journal of Chronic Obstructive Pulmonary Disease 2011; 6: 659-67.

  38. Douglas F, Torrance N, van Teijlingen E, Meloni S, Kerr A. Primary care staff’s views and experiences related to routinely advising patients about physical activity. A questionnaire survey. BMC public health 2006; 6: 138.

  39. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-23.

  40. Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA, Rubin HR. Why don’t physicians follow clinical practice guidelines? A framework for improvement. JAMA 1999; 282: 1458-65.

  41. Derksen RE, Brink-Melis WJ, Westerman MJ, Dam JJ, Seidell JC, Visscher TL. A local consensus process making use of focus groups to enhance the implementation of a national integrated health care standard on obesity care. Family practice 2012; 29(Suppl. 1): i177-i184.




2020     |     www.medigraphic.com